Morphiex Biotherapeutics | Data with Morphiex’s CD47 inhibitor (MBT-001) to be featured as an Oral Presentation at the 2019 Society for Immunotherapy for Cancer (SITC) Conference
575
post-template-default,single,single-post,postid-575,single-format-standard,ajax_fade,page_not_loaded,,qode-title-hidden,qode-content-sidebar-responsive,qode-theme-ver-13.8,qode-theme-bridge,disabled_footer_top,disabled_footer_bottom

Data with Morphiex’s CD47 inhibitor (MBT-001) to be featured as an Oral Presentation at the 2019 Society for Immunotherapy for Cancer (SITC) Conference

New Data with MBT-001

An oral presentation (#O8) featuring our #CD47 inhibitor (MBT-001) titled “The Thrombospondin-1/CD47 signaling axis serve as potential markers of immune checkpoint blockade response modulating immune cell bioenergetics in the tumor microenvironment” will be presented on Saturday, November 9th, 2019 at the Gaylord National Hotel & Convention Center in Washington, DC.

The presentation is part of the Presidential Session (306) and will be held at 3:05 PM EST on Saturday, November 9th, 2019.

Data presented were generated by our collaborators at The Wake Forest School of Medicine.

About MBT-001

MBT-001 was developed at the National Cancer Institute (NCI) at the National Institutes of Health (NIH). MBT-001 is exclusively licensed to Morphiex for the treatment of cancer as a monotherapy or in combination with other modalities such as chemotherapy, immune checkpoint inhibitors, CAR-T and many others. Morphiex has entered into a cooperative research and development agreement (CRADA) with the NIH/NCI to accelerate the development of MBT-001. In addition, Morphiex is in a pre-clinical and clinical collaboration with the Wake Forest School of Medicine with regards to MBT-001.



Location

240 Newbury Street, 2nd Floor
Boston, MA
info@morphiex.com

Social Media

Twitter Facebook LinkedIn